Affiliation
Department of Pharmacology, University of California, San Diego, La Jolla, CA 92093-0721, USAIssue Date
2017-03-07
Metadata
Show full item recordAbstract
The discovery in the 1980s that protein kinase C (PKC) is a receptor for the tumor-promoting phorbol esters fueled the dogma that PKC is an oncoprotein. Yet 30+ years of clinical trials for cancer using PKC inhibitors not only failed, but in some instances worsened patient outcome. The recent analysis of cancer-associated mutations, from diverse cancers and throughout the PKC family, revealed that PKC isozymes are generally inactivated in cancer, supporting a tumor suppressive function. In keeping with a bona fide tumor suppressive role, germline causal loss-of-function (LOF) mutations in one isozyme have recently been identified in lymphoproliferative disorders. Thus, strategies in cancer treatment should focus on restoring rather than inhibiting PKC.Citation
Reversing the paradigm: protein kinase C as a tumor suppressor. 2017, Trends Pharmacol SciJournal
Trends in Pharmacological SciencesDOI
10.1016/j.tips.2017.02.002PubMed ID
28283201Type
ArticleLanguage
enISSN
1873-3735ae974a485f413a2113503eed53cd6c53
10.1016/j.tips.2017.02.002
Scopus Count
Collections
Related articles
- Protein kinase C as a tumor suppressor.
- Authors: Newton AC
- Issue date: 2018 Feb
- Protein kinase C: perfectly balanced.
- Authors: Newton AC
- Issue date: 2018 Apr
- Cancer-associated protein kinase C mutations reveal kinase's role as tumor suppressor.
- Authors: Antal CE, Hudson AM, Kang E, Zanca C, Wirth C, Stephenson NL, Trotter EW, Gallegos LL, Miller CJ, Furnari FB, Hunter T, Brognard J, Newton AC
- Issue date: 2015 Jan 29
- PHLPPing the balance: restoration of protein kinase C in cancer.
- Authors: Tovell H, Newton AC
- Issue date: 2021 Jan 29
- Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression.
- Authors: Isakov N
- Issue date: 2018 Feb